Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

s activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

BIOMARIN PHARMACEUTICAL INC.CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars, except share and per share amounts)September 30,
2011December 31,
2010 (1)(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$

71,254$

88,079Short-term investments153,120186,033Accounts receivable, net (allowance for doubtful accounts: $839 and $63, respectively)107,05786,576Inventory115,628109,698Other current assets39,96533,874Total current assets487,024504,260Investment in BioMarin/Genzyme LLC1,1681,082Long-term investments145,640128,171Property, plant and equipment, net266,190221,866Intangible assets, net100,780103,648Goodwill51,54353,364Long-term deferred tax assets229,172236,017Other assets13,55914,215Total assets$

1,295,076$

1,262,623LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable and accrued liabilities$

83,254$

83,844Total current liabilities83,25483,844Convertible debt348,339377,521Other long-term liabilities88,94484,001Total liabilities520,537545,366Stockholders’ equity:Common stock, $0.001 par value
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
3. BioMarin to Present at the Baird Health Care Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. BioMarin Announces Second Quarter 2011 Financial Results
6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
8. BioMarin to Present at the William Blair Growth Stock Conference
9. BioMarin to Present at the Jefferies Global Healthcare Conference
10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
11. BioMarin Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/22/2014)... influenced by low exposure to testosterone in the womb, ... men,s testosterone levels may be determined before they are ... the hormone than others is important because testosterone is ... hormone have been linked to obesity, diabetes and heart ... for producing testosterone in adults known as Leydig ...
(Date:4/22/2014)... fiction: In enemy territory, activate your cloaking device. And ... to the immune system. Now scientists at Harvard,s Wyss ... tactics to build the first DNA nanodevices that survive ... the way for smart DNA nanorobots that could use ... doctors can today; target drugs to tumors, or even ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Toronto say a sleep disorder that ... best current predictor of brain diseases like Parkinson,s and ... not just a precursor but also a critical warning ... says associate professor and lead author Dr. John Peever. ... cent of people with RBD will develop a brain ...
(Date:4/21/2014)... Minn. Acute respiratory distress syndrome is a ... who develop the lung disorder postoperatively are at ... those who survive the syndrome may still bear ... Mayo Clinic-led study is helping physicians better identify ... preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... New York, NY (June 6, 2012) A clinical ... molecular therapy called vismodegib (trade name Erivedge), can dramatically ... of new ones, in patients with basal cell nevus ... sometimes hundreds or thousands, of skin cancers on each ...
... In a Phase 2 study presented at the ... Oncology (ASCO), clinical researchers from University Hospitals Case Medical ... to treat gynecologic cancers, shortening radiation treatment time from ... stereotactic body radiotherapy (SBRT), has been used on other ...
... THURSDAY, May 31 (HealthDay News) -- Live chicks and ducklings ... a salmonella outbreak that had sickened 93 people in 23 ... in an update Thursday. Eighteen people have been ... under investigation. Among the reported cases so far, illnesses surfaced ...
... , THURSDAY, May 31 (HealthDay News) -- Meat, ... associated with a fivefold increased risk of immediate gout flare-ups, ... arthritis that often first occurs in the big toe. Anecdotal ... but it hasn,t been clear whether they cause immediate attacks. ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Steven Reinberg HealthDay Reporter , THURSDAY, May 31 ... the United States may be infected with chronic hepatitis B ... come from countries in Asia and Africa, where regular vaccination ... "Hepatitis B is a common infection transmitted at birth or ...
Cached Medicine News:Health News:New drug found effective against rare form of basal cell skin cancer 2Health News:New drug found effective against rare form of basal cell skin cancer 3Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 2Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 3Health News:Ohio Mail-Order Hatchery Now Linked to Salmonella in 23 States 2Health News:Gout Flare-ups Rise Sharply With Certain Foods: Study 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: